Sign in

    Jenny Leigh Gonzalez-Armenta

    Research Analyst at Leerink Partners

    Jenny Leigh Gonzalez-Armenta, PhD, is an Equity Research Associate at Leerink Partners specializing in diversified biopharmaceuticals, where she contributes to investment recommendations and detailed fundamental research. She covers several notable companies including Janux Therapeutics, Pyxis Oncology, Xencor, and Zai Lab, and supports senior analysts in producing actionable insights for institutional clients. Gonzalez-Armenta began her financial career at Leerink Partners following scientific roles at Jaguar Gene Therapy and as a research fellow at Wake Forest School of Medicine, joining Leerink after completing her PhD in Molecular Medicine and Translational Science from Wake Forest University School of Medicine. She is FINRA registered under CRD# 7620465, demonstrating compliance with industry regulatory standards.

    Jenny Leigh Gonzalez-Armenta's questions to uniQure (QURE) leadership

    Jenny Leigh Gonzalez-Armenta's questions to uniQure (QURE) leadership • Q1 2025

    Question

    Jenny Leigh Gonzalez-Armenta, on for Joseph Schwartz, asked about the new CBER head's views on patient advocacy groups, uniQure's relationship with the Huntington's Disease Society of America, and the general sentiment of the HD community.

    Answer

    CMO Dr. Walid Abi-Saab emphasized uniQure's long and productive history with patient advocacy groups like CHDI, stating their work and sophisticated natural history data have been essential for the field. He described these organizations as extremely balanced, well-respected by the FDA, and crucial partners, noting that without them, uniQure and others would not be where they are today.

    Ask Fintool Equity Research AI

    Jenny Leigh Gonzalez-Armenta's questions to Wave Life Sciences (WVE) leadership

    Jenny Leigh Gonzalez-Armenta's questions to Wave Life Sciences (WVE) leadership • Q1 2025

    Question

    Jenny Leigh Gonzalez-Armenta from Leerink Partners asked about the potential benefits of exceeding the 11 micromolar AAT protein threshold in the Alpha-1 program and the key differentiators between RNA and DNA editing from a patient's perspective.

    Answer

    President and CEO Dr. Paul Bolno stated that exceeding the 11 micromolar threshold could offer additional benefits, such as faster clearance of liver aggregates, and that upcoming multi-dose data will be crucial. He contrasted RNA editing with DNA editing by highlighting the risks of bystander edits and misfolded proteins with DNA-based approaches. He also noted a key patient-centric advantage: Wave's GalNAc-conjugated WVE-006 avoids the need for LNP delivery, which carries a risk of hepatic injury, a significant concern for patients with liver disease.

    Ask Fintool Equity Research AI